Genmab A/S

ISIN US3723032062

 | 

WKN A1WZYB

Market cap (in EUR)
18,484 m
Country
Denmark
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
Show more Show less
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals Denmark

Financials

Key metrics

Market capitalisation, EUR 18,484 m
EPS, EUR 2.15
P/B ratio 3.6
P/E ratio 14.2
Dividend yield 0.00%

Income statement (2024)

Revenue, EUR 2,886 m
Net income, EUR 1,052 m
Profit margin 36.44%

What ETF is Genmab A/S in?

There are 5 ETFs which contain Genmab A/S. All of these ETFs are listed in the table below. The ETF with the largest weighting of Genmab A/S is the First Trust NYSE Arca Biotechnology UCITS ETF Acc.
ETF Weight Investment focus Fund size (in m EUR)
WisdomTree Megatrends UCITS ETF USD 0.08%
Equity
World
Social/Environmental
Innovation
26
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.10%
Equity
United States
Health Care
Biotech
46
iShares Nasdaq US Biotechnology UCITS ETF 0.10%
Equity
United States
Health Care
Biotech
750
First Trust NYSE Arca Biotechnology UCITS ETF Acc 2.84%
Equity
United States
Health Care
Biotech
12
WisdomTree BioRevolution UCITS ETF USD Acc 1.17%
Equity
World
Health Care
Social/Environmental
Biotech
8
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.